London Calling Technology Update

Oxford Nanopore Technologies plc

21 May 2026

 

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

London Calling Technology Update

Annual customer conference highlights customer-led execution and continued platform innovation

21 May 2026

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based sensing technology, presented a Technology Update at the Company's flagship annual London Calling customer conference.

Opening London Calling 2026, Chief Executive Francis Van Parys highlighted the Company's continued focus on customer-led platform development, strengthening the user end‑to‑end experience and supporting broader adoption in applied and regulated environments. He also underlined ongoing investment in longer-term innovation to extend platform capabilities.

At the Annual Technology Talk the Company highlighted updates including:

Platform development led by customer need

·      Delivering richer multiomic insight from a single platform: advances in integrated DNA, RNA and epigenetic data, including methylation, providing comprehensive insight from a single system.

·     Driving continuous improvement in platform performance, including accuracy, base modifications, output and speed, with continued enhancement of unique features such as adaptive sampling. This includes the introduction of the PromethION Plus Flow Cell, designed to increase output with enhanced yield achieved without additional wash and reload steps. The Company also highlighted increasing use of AI-driven methods across basecalling, variant detection and downstream analysis.

·     Expanding platform capability across core workflows, including transcriptomics (RNA), microbial and vaccine QC (GridION Q), and high-output sequencing (PromethION), with new chemistry and workflows shipping from May to July 2026.

Regulatory readiness

·      Advancing reliability and consistency: improvements in repeatability and robust performance in production environments, enabling predictable use at scale.

·      Expanding real-world deployment across routine and regulated settings.

End-to-end experience

·      Simplifying workflows and reducing complexity to support broader adoption.

·      Advancing integrated software platforms, including EPI2ME, for accessible and standardised data interpretation.

Longer-term innovation and platform pipeline

·      Continuing investment across chemistry and hardware towards both low and high output applications, and development of multiomic capability including protein sequencing, extending the platform into new areas of biological insight.

·      Showcasing a novel demonstration of peptide sequencing using an amino-acid calling for accurate protein identification.

A video replay of the Technology Talk is available on the Oxford Nanopore website here.

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:     [e-mail] 

Media:           [e-mail] 

Teneo (communications adviser to the Company)

Tom Murray and Lisa Jarrett-Kerr

[phone]

[e-mail] 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: www.nanoporetech.com

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, delays or challenges in manufacturing or delivering of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance or applied uses of our products. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

 

END